These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26337851)

  • 21. Similarities and differences between patients fulfilling axial and peripheral ASAS criteria for spondyloarthritis: Results from the Esperanza Cohort.
    del Río-Martínez P; Navarro-Compán V; Díaz-Miguel C; Almodóvar R; Mulero J; De Miguel E;
    Semin Arthritis Rheum; 2016 Feb; 45(4):400-3. PubMed ID: 26601781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
    Dubash S; Marianayagam T; Tinazzi I; Al-Araimi T; Pagnoux C; Weizman AV; Richette P; Tran Minh ML; Allez M; Singh A; Ciccia F; Hamlin J; Tan AL; Marzo-Ortega H; McGonagle D
    Rheumatology (Oxford); 2019 Jun; 58(6):963-968. PubMed ID: 30204909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
    Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
    Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic intestinal inflammation and seronegative spondyloarthropathy in children.
    Conti F; Borrelli O; Anania C; Marocchi E; Romeo EF; Paganelli M; Valesini G; Cucchiara S
    Dig Liver Dis; 2005 Oct; 37(10):761-7. PubMed ID: 16024303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rheumatic manifestations in inflammatory bowel disease.
    Atzeni F; Defendenti C; Ditto MC; Batticciotto A; Ventura D; Antivalle M; Ardizzone S; Sarzi-Puttini P
    Autoimmun Rev; 2014 Jan; 13(1):20-3. PubMed ID: 23774109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis.
    Strand V; Rao SA; Shillington AC; Cifaldi MA; McGuire M; Ruderman EM
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1299-306. PubMed ID: 23436774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease.
    Beslek A; Onen F; Birlik M; Akarsu M; Akar S; Sari I; Gurler O; Akpinar H; Manisali M; Akkoc N
    Rheumatol Int; 2009 Jun; 29(8):955-7. PubMed ID: 19082597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of spondyloarthritis symptom in inflammatory bowel disease patients: A questionnaire survey.
    Kamo K; Shuto T; Haraguchi A
    Mod Rheumatol; 2015 May; 25(3):435-7. PubMed ID: 25381725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
    Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The joint-gut axis in inflammatory bowel diseases.
    Brakenhoff LK; van der Heijde DM; Hommes DW; Huizinga TW; Fidder HH
    J Crohns Colitis; 2010 Sep; 4(3):257-68. PubMed ID: 21122514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis.
    Di Carlo M; Luchetti MM; Benfaremo D; Di Donato E; Mosca P; Maltoni S; Benedetti A; Gabrielli A; Grassi W; Salaffi F
    Clin Rheumatol; 2018 Apr; 37(4):1037-1044. PubMed ID: 29204760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.
    de Vlam K; Mielants H; Cuvelier C; De Keyser F; Veys EM; De Vos M
    J Rheumatol; 2000 Dec; 27(12):2860-5. PubMed ID: 11128677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Macaluso FS; Fries W; Viola A; Costantino G; Muscianisi M; Cappello M; Guida L; Giuffrida E; Magnano A; Pluchino D; Ferracane C; Magrì G; Di Mitri R; Mocciaro F; Privitera AC; Camilleri S; Garufi S; Renna S; Casà A; Scrivo B; Ventimiglia M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1381-1384. PubMed ID: 32981373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
    Lehtola E; Haapamäki J; Färkkilä MA
    Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current issues in pediatric inflammatory bowel disease-associated arthropathies.
    Cardile S; Romano C
    World J Gastroenterol; 2014 Jan; 20(1):45-52. PubMed ID: 24415857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.
    Spadaro A; Lubrano E; Marchesoni A; Cauli A; Cantini F; Carotti M; D'Angelo S; Grassi W; Lapadula G; Macchioni P; Mathieu A; Punzi L; Ramonda R; Salaffi F; Salvarani C; Scarpa R; Olivieri I
    Clin Exp Rheumatol; 2014; 32(4):465-70. PubMed ID: 24850468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.